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Aims: The effects of hormone replacement therapy with estrogen on cardiovascular disease in postmenopausal
women are still controversial. In the present study, we examined the effects of an endothelin (ET) receptor
antagonist (ERA) and/or angiotensin receptor blocker (ARB) on neointimal formation following vascular injury
in ovariectomized (OVX) female rats.
Mainmethods: Female ratswere divided into intact female andOVX groups. The right carotid arterywas subjected
to balloon injury, and harvested 2 weeks later.
Key ﬁndings: In the intact female groups, treatment with ARB (L-158809; 1 mg/kg/day) for two weeks after the
injury signiﬁcantly decreased neointimal formation, whereas treatment with the ERA (J-104132; 10 mg/kg/day)
did not affect neointimal formation. On the other hand, the ERAmarkedly decreased neointimal formation after
the injury in the OVX groups; however, neointimal formation was not signiﬁcantly improved by the ARB
treatment. In addition, the combined treatmentwith 17β-estradiol (20 μg/kg/day) or the ERA and ARBmarkedly
suppressed neointimal formation after the balloon injury in the OVX groups, whereas no combinational effects
were observed due to the combined treatment with 17β-estradiol and the ERA.
Signiﬁcance: These results suggest that ERAs have estrogen-like vasoprotective effects on neointimal formation
following balloon injury in OVX rats. ERAs may be useful as an alternative therapy to prevent vascular disease
in postmenopausal women.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/ .0/).3Introduction
The incidence of cardiovascular disease has been shown to be lower
in women prior to menopause than in men and postmenopausal
women (Mahendru and Morris, 2013; Maranon and Reckelhoff, 2013).
The mechanisms underlying these lower risks in premenopausal
women have not been elucidated completely, but can at least be partly
explained by the vasoprotective effects of estrogen (Bernelot Moens
et al., 2012; Farhat et al., 1996; Pare et al., 2002). Previous studies
showed that estrogen increased endothelial nitric oxide production
and suppressed smooth muscle proliferation/migration, oxidative
stress, and inﬂammation in the vessels (Florian et al., 2004; Miller
et al., 2003; Tolbert et al., 2001). Several clinical studies reported the
beneﬁcial effects of estrogen replacement therapy (ERT) on the risk of
cardiovascular diseases in postmenopausal women (Grady et al.,
1992; Walsh et al., 1991). In contrast, other clinical trials, including
the Heart and Estrogen–Progestin Replacement Study (HERS) andl and Molecular Pharmacology,
sahara, Takatsuki, Osaka 569-
ura).
. This is an open access article underWomen's Health Initiative (WHI) Clinical Trial and observational
study, found no beneﬁcial effects of ERT (Hulley et al., 1998; Rossouw
et al., 2002). Thus, the efﬁcacy of ERT on cardiovascular disease is still
controversial in clinical settings. Elucidating the mechanisms of
estrogen-induced vasoprotective effects and alternative estrogen thera-
pies in postmenopausal women in more detail remains a critical issue.
Endothelin (ET)-1 exhibits potent vasoconstriction and mitogenic
effects on vascular smooth muscle cells (VSMCs) (Kirchengast and
Munter, 1998; Kitada et al., in press; Ohkita et al., 2012). The ET-1/ET
receptor system-induced proliferation of VSMCs and neointimal
formation are known to be involved in the development of vascular
diseases such as atherosclerosis, restenosis, and hypertension or
diabetes-induced arterial hypertrophy; therefore, endothelin receptor
antagonists (ERAs) may be used as vasoprotective drugs to treat vascu-
lar diseases (Kirchengast and Munter, 1998; Kitada et al., in press).
Previous studies showed that the ET-1/ET receptor system is closely
related to the sex differences associated with cardiovascular diseases
(Kawanishi et al., 2007; Kitada et al., 2011; Lekontseva et al., 2010;
Tostes et al., 2008). For example, plasma ET-1 concentrations were
shown to be lower in women than in men and old women had higher
plasma ET-1 levels than young women (Best et al., 1998; Maeda
et al., 2003; Miyauchi et al., 1992). In addition, the administration ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ .0/).3
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postmenopausal women (Best et al., 1998). Moreover, previous studies
reported that estrogen could regulate the production and function of
ET-1 as well as ET receptor expression in the cardiovascular system
(Dubey et al., 2001; Kitada et al., in press; Lekontseva et al., 2010;
Pedersen et al., 2008; Tostes et al., 2008). We previously demonstrated
that ET receptor-mediated ET-1 actionswere stronger in the vascular le-
sion sites of males than in those of intact females (Kitada et al., 2011).
These results indicate that the inhibitory effects of estrogen on the ET
system contribute to themechanisms underlying the sex differences as-
sociated with cardiovascular diseases. Thus, the vascular ET-1/ET recep-
tor system may be augmented and contribute to the increase in the
incidence of cardiovascular events in postmenopausal women because
of estrogen deﬁciencies. Taken together, ERAs may be a new target to
replace estrogen and become an effective therapy for reducing the risk
of cardiovascular diseases after menopause.
In the present study, we hypothesized that an ERA may effectively
prevent the development of vascular lesions in OVX female rats as a re-
placement for estrogen. To conﬁrm this hypothesis, we examined the
vasoprotective effects of an ERA on balloon injury-induced neointimal
formation in intact and ovariectomized (OVX) female rats and
compared these effects with those of angiotensin receptor blockade
(ARB), which is one of the key vasoprotective drugs used in clinical
cases (Hernandez Schulman et al., 2007; Nakashima et al., 2006).
Materials and methods
Animals
Animals were housed in a light-controlled room with a 12-hour
light/dark cycle and were allowed ad libitum access to food and water.
Experimental protocols and animal care methods in the experiments
were approved by the Experimental Animal Committee at Osaka
University of Pharmaceutical Sciences, and all studies were conducted
in accordance with the National Institutes of Health Guide for the Care
and Use of Laboratory Animals.
Experimental protocols
Female Sprague–Dawley (SD) rats (9 weeks old, Japan SLC, Shizuoka,
Japan) were divided into intact female and OVX groups. Ovariectomy
or sham surgery was performed under anesthesia using an intraperito-
neal injection of ketamine (80 mg/kg) and xylazine (5 mg/kg).
Rats underwent balloon injury to the right carotid artery one week
after surgery. Some intact female and OVX rats were gavaged with
J-104132 (an ETA/ETB dual receptor antagonist: 10 mg/kg/day), (+)-
(5S,6R,7R)-2-butyl-7-[2-((2S)-2-carboxypropyl)-4-methoxyphenyl]-5-
(3,4-methylenedioxyphenyl)cyclopenteno[1,2-b]pyridine-6-carboxylic
acid, and/or L-158809 (an AT1 receptor antagonist: 1 mg/kg/day),
5,7-dimethyl-(2-ethyl-3-[[2′-(1H-tetrazol-5-yl)[1,1′]-biphenyl-4-
yl]methyl]-3H-imidazo[4,5-b] pyridine, for 2 weeks starting 12 h after
the balloon injury. Furthermore, some OVX rats were treated daily
with the subcutaneous administration of 17β-estradiol (20 μg/kg/day)
and/or ICI 182,780 (an estrogen receptor inhibitor: 5 mg/kg/day)
starting 24 h before the balloon injury, with or without J-104132 or
L-158809. The administration of J-104132, L-158809, 17β-estradiol,
ICI 182,780, or vehicle was continued until 2 weeks after the balloon
injury. The doses of these drugs were determined based on previous
studies (Bakir et al., 2000; Huckle et al., 1996; Kitada et al., 2009,
2011). We also determined the effects of these doses of J-104132
and L-158809 in male rats in separate experiments. Relative to the
vehicle treatment, J-104132 or L-158809 signiﬁcantly suppressed
the neointima/media ratio to the same extent (0.71 ± 0.09 vs 0.42 ±
0.06 or 0.46 ± 0.06, respectively, P b 0.05, n = 4 per group). We used
the following 12 groups in this study.1) intact + vehicle
2) intact + ERA
3) intact + ARB
4) OVX + vehicle
5) OVX + ERA
6) OVX + ERA + ICI 182,780
7) OVX + ARB
8) OVX + 17β-estradiol
9) OVX + 17β-estradiol + ICI 182,780
10) OVX + 17β-estradiol + ERA
11) OVX + 17β-estradiol + ARB
12) OVX + ERA + ARB
Balloon injury model
Rats were anesthetized using an intraperitoneal injection of ketamine
(80 mg/kg) and xylazine (5 mg/kg), and the right carotid artery was in-
jured with a 2 F Fogarty balloon catheter (Baxter International, Deerﬁeld,
IL, USA), as described previously (Kurumazuka et al., 2006). The left carot-
id arterywas not damaged. Rats were sacriﬁced 2 days and 2 weeks after
the balloon injurywith a sodiumpentobarbital overdose (75 mg/kg), and
both the left and right carotid arteries were harvested.
Morphometric analysis
The bilateral carotid arteries 2 weeks after the balloon injury were
ﬁxed in 10% formalin, embedded in parafﬁn, and cut into 4 μm-thick sec-
tions. Tissue sectionswere stained using the Elastica VanGiesonmethod.
Morphometric analysis of each arterial segment was performed with a
computer-basedMotic Image Plus 2.0Morphometric system (Shimadzu,
Kyoto, Japan). The border of the lumen, internal elastic lamina, and exter-
nal elastic laminawere traced and the neointimal andmedial areas were
measured. The ratio of the neointimal to medial area (neointima/media
ratio) was calculated by dividing the neointimal area by themedial area.
NADPH-dependent superoxide production
NADPH oxidase activity was measured based on the degree of
NADPH-dependent superoxide production in the isolated carotid
arteries, as assessed by a lucigenin-enhanced assay. We examined
NADPH-dependent superoxide production 2 days after the balloon inju-
ry based on our previous study (Kurumazuka et al., 2006). Brieﬂy, both
injured (right) and uninjured (left) common carotid arteries were
cleared of adherent adipose and loose connective tissue in situ and
were harvested in ice-cold modiﬁed Krebs–HEPES buffer containing
(in mmol/L): NaCl 99.01, HEPES 20, KCl 4.69, MgSO4 0.59, KH2HPO4
1.03, NaHPO4 25, CaCl2 1.41, and glucose 11.1 (pH 7.4). The tissues
were then gently ﬂushed with cold buffer to remove blood from the
lumen and were cut into 3 segments. The segments were incubated
with NADPH (100 μmol/L) in buffer at 37 °C for 15 min. Lucigenin-
enhanced chemiluminescence was measured in 2 mL Krebs–HEPES
buffer containing lucigenin (5 μmol/L) using a Berthold FB12 single-
tube luminometer, modiﬁed to maintain a sample temperature of
37 °C. Chemiluminescence was measured continuously for 15 min
after allowing for dark adaptation and was expressed as relative light
units per minute per milligram vessel dry weight (RLU/min/mg).
Drugs
17β-Estradiol and ICI 182,780 were obtained from Nacalai Tesque
(Kyoto, Japan) and Sigma Chemical Co. (St. Louis, MO), respectively
and dissolved in cottonseed oil. J-104132 and L-158809 were provided
by Banyu Pharmaceutical Co., Ltd. (Tsukuba, Japan) and Merck & Co.
Inc (Rahway, USA), respectively, and dissolved in distilled water.
Other chemicals were purchased from Sigma Chemical Co., Nacalai
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All values were expressed as the mean± S.E.M. Relevant data were
processed by InStat (Graph-PAD Software for Science, San Diego, CA).
We used a one-way analysis of variance (ANOVA) followed by
Dunnett's multiple comparison tests for statistical analysis. Differences
















Fig. 2. Neointima/media ratio of the injured arteries in intact female rats 2 weeks after the
balloon injury. Data are expressed as themean± S.E.M. (n= 6–8). *P b 0.05, signiﬁcantly
different from the vehicle-treated intact female group. ERA; endothelin receptor antagonist
(10 mg/kg/day, p.o.), ARB; angiotensin receptor blocker (1 mg/kg/day, p.o.).Results
Effects of the ERA or ARB on neointimal formation in intact female and
OVX rats
Neointimal formation after the balloon injury was not observed in
the uninjured arteries of all groups (data not shown).
In the injured arteries of the intact female groups, ARB, but not the
ERA treatment markedly reduced the extent of neointimal formation
following the balloon injury (Fig. 1A–C). The ERA treatment did not sig-
niﬁcantly decrease the neointima/media ratio after the balloon injury in
intact female rats,whereas theARB treatment did (Fig. 2). However, dif-
ferent results were observed in the OVX groups. The ERA treatment
markedly decreased neointimal formation and the neointimal/media
ratio in the injured arteries of theOVX groups (Figs. 1D, E and 3),where-
as the ARB treatment did not (Figs. 1F and 3).Effects of the combined therapy with the ERA, ARB, and 17β-estradiol on
neointimal formation in OVX rats
The neointima/media ratio was signiﬁcantly lower in the 17β-
estradiol-treated OVX groups than in the vehicle-treated group
(Fig. 3). The combined treatment with 17β-estradiol and ARB further
decreased the neointima/media ratio after the balloon injury in the
OVX groups, whereas no combinational effects were observed due to
the combined treatment with 17β-estradiol and the ERA (Fig. 3). The
combined treatment with the ERA and ARB had an additive effect on











Fig. 1. Lightmicrographs of an injured carotid artery 2 weeks after the balloon injury in (A–C) intac
(C and F) ARB (L-158809; 1 mg/kg/day, p.o.) (Elastica Van Gieson staining, magniﬁcation ×200).Effects of an estrogen receptor inhibitor on ERA or 17β-estradiol-induced
inhibition of neointimal formation in OVX rats
The ERA exhibited estrogen-like vasoprotective effects on balloon
injury-induced neointimal formation in OVX rats. Thus, we examined
whether the vasoprotective effects of the ERA were dependent on the
estrogen receptor. Treatment with ICI 182,780, an estrogen receptor
inhibitor, did not signiﬁcantly increase the neointima/media ratio fol-
lowing the balloon injury in ERA-treated OVX rats, and 17β-estradiol-
induced vasoprotective actionswere abolished by ICI 182,780 treatment
(Fig. 3).
Effects of monotherapy or the combined therapy with the ERA, ARB, and
17β-estradiol on oxidative stress in intact and OVX rats
No signiﬁcant differences were observed in NADPH-dependent






t female and (D–F)OVX rats. (A andD) vehicle, (B andE) ERA (J-104132; 10 mg/kg/day, p.o.),





















































Fig. 3.Neointima/media ratio of the injured arteries in OVX rats 2 weeks after the balloon injury. Data are expressed as themean± S.E.M. (n= 4–7). *P b 0.05, signiﬁcantly different from
the vehicle-treated OVX group, #P b 0.05, signiﬁcantly different from the ARB-treated OVX group, †P b 0.05, signiﬁcantly different from the E2-treated OVX group. OVX; ovariectomy, ERA;
endothelin receptor antagonist (10 mg/kg/day, p.o.), ARB; angiotensin receptor blocker (1 mg/kg/day, p.o.), E2; 17β-estradiol (20 μg/kg/day, s.c.), ICI; ICI 182,780 (5 mg/kg/day, s.c.).
382 K. Kitada et al. / Life Sciences 118 (2014) 379–385The ARB treatment signiﬁcantly suppressed NADPH-dependent
superoxide production in the injured arteries of the intact female groups
2 days after the balloon injury, whereas the ERA treatment did not
(Fig. 4B). On the other hand, the ERA or 17β-estradiol treatment signif-
icantly reduced NADPH-dependent superoxide production in the
injured arteries of the OVX groups 2 days after the balloon injury
(Fig. 4B). In contrast, the ARB treatment failed to suppress NADPH-
dependent superoxide production in the injured arteries of the
OVX groups (Fig. 4B). The combined treatment with the ERA or 17β-
estradiol and ARB markedly suppressed NADPH-dependent superoxide
production 2 days after the balloon injury in the OVX groups; however,
no combinational effects were observed due to the combined treatment
with the ERA and 17β-estradiol (Fig. 4B).
Discussion
ET-1 and its receptor system are known to be augmented in the ves-
sels following vascular injury, and this system is involved in the devel-
opment of vascular diseases (Douglas et al., 1994; Kirchengast and
Munter, 1998; Kitada et al., in press). In addition, the ET system was
shown to be at least partly responsible for the sex differences associated
with vascular disease (Kitada et al., in press; Lekontseva et al., 2010;
Tostes et al., 2008). On the other hand, previous studies suggested
that estrogen suppresses the ET system and may contribute to the
lower risk of cardiovascular diseases in premenopausal females; how-
ever, the detailed mechanism responsible remains unclear (Kitada
et al., 2011; in press; Lekontseva et al., 2010; Tostes et al., 2008). Thus,
the vasoprotective effects caused by ERAs inmales and postmenopausal
females may be superior to those in intact females because estrogen
could already inhibit the augmentation of the vascular ET system fol-
lowing an injury in premenopausal females. We previously reported
that both a selective ETA receptor antagonist and ETA/ETB dual receptor
antagonist signiﬁcantly reduced neointimal formation following a bal-
loon injury in male rats, but did not in intact female rats (Kitada et al.,
2011). These results suggested sex differences in the vasoprotective ef-
fects of ERAs and also that ET receptor-induced neointimal formation
following a balloon injury in intact female rats is less than that observed
in male rats. In the present study, we demonstrated that the ERAmark-
edly suppressed neointimal formation following a balloon injury in OVX
rats, but not in intact females. This result conﬁrmed that ERAs havesuperior vasoprotective effects, particularly in estrogen-deﬁcient situa-
tions such as OVX and menopause. Thus, ERAs will be an effective tool
that can replace estrogen in order to reduce the risk of vascular diseases
after menopause.
OVXhas been shown to causemore robust neointimal formation fol-
lowing vascular injury than that observed in intact female rats, and the
administration of estrogen to OVX rats attenuated neointimal formation
(Chen et al., 1996; Kitada et al., 2011). In addition, an estrogen receptor
inhibitor aggravated neointimal formation in intact female and
estrogen-treated OVX rats (Bakir et al., 2000). These results suggest
that estrogen and its receptor system are an important factor for de-
creased neointimal formation in female rats. In the present study, the
ERA exhibited estrogen-like vasoprotective effects in female rats. There-
fore, we examined whether ERA-induced actions were mediated by the
estrogen receptor. ICI 182,780, an estrogen receptor inhibitor, did not
affect neointimal formation following the balloon injury in the ERA
treatment group; however, the 17β-estradiol-induced reduction in neo-
intimal formationwas abolished by the ICI 182,780 treatment. These re-
sults suggest that ERA-induced vasoprotective effects in OVX rats are
independent of the estrogen receptor, but may be closely related to
downstream pathways for estrogen receptor-mediated vasoprotective
effects. No combinational effects are associated with reducing neointi-
mal formation due to the combined treatment with the ERA and 17β-
estradiol. Thus, there is some overlap in the mechanisms underlying
vasoprotective effects between the ERA and estrogen.However, we can-
not completely deny the possibility that the vasoprotective effect of the
ERA in OVX rats may have been inhibited by the estrogen receptor in-
hibitor because no signiﬁcant difference was observed in the neointi-
ma/media ratio between OVX and OVX + ERA + ICI. The detailed
mechanisms underlying ERA-induced vasoprotective effects under
estrogen-deﬁcient conditions remain unclear. An analysis of the
crosstalk between estrogen and ET is needed in order to more fully
understanding the pharmacological mechanisms underlying the
vasoprotective actions induced by ERAs and estrogen.
Previous studies reported that ET-1 caused vascular disease via the
induction of inﬂammation and oxidative stress, increases in growth
factors (PDGF and FGF) and proliferative factors (EGF), and production
of collagen and extracellular matrix (Bohm and Pernow, 2007;
Kirchengast and Munter, 1998; Little et al., 2008; Takahashi, 2006).
These ET-1-induced vascular injuries were shown to be mainly




























































Fig. 4.NADPH-dependent superoxide production in (A) uninjured and (B) injured carotid arteries 2 days after the balloon injury. *P b 0.05, signiﬁcantly different from the vehicle-treated
intact or OVX group, #P b 0.05, signiﬁcantly different from the ARB-treated OVX group. OVX; ovariectomy, ERA; endothelin receptor antagonist (10 mg/kg/day, p.o.), ARB; angiotensin
receptor blocker (1 mg/kg/day, p.o.), E2; 17β-estradiol (20 μg/kg/day, s.c.).
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demonstrated that the ET-1/ETA receptor system plays an important
role in the development of vascular disease (Douglas et al., 1994;
Kitada et al., 2009; Takahashi, 2006; Wang et al., 1996). In addition, se-
lective ETA receptor and dual ETA/ETB receptor antagonists were shown
to have vasoprotective effects (Douglas et al., 1994; Kitada et al., 2009;
Takahashi, 2006; Wang et al., 1996). Meanwhile, understanding the
pathological role of the ET-1/ETB receptor system in vascular diseases
has not been fully elucidated because of its opposing effects on endothe-
lial and vascular smooth muscle cells; the endothelial ETB receptor
induces vasoprotective effects in injured vessels,whereas the ETB recep-
tor in vascular smooth muscle cells induces vascular injury (Kirkby
et al., 2012; Kitada et al., 2009; Murakoshi et al., 2002; Ohkita et al.,
2012). With regard to this issue, we reported that inhibiting the ETB re-
ceptor system aggravated neointimal formation following a balloon in-
jury inmale rats and also that the chronic inhibition of ETB receptors led
to the overstimulation and/or upregulation of the ETA receptor system
(Kitada et al., 2009). These ﬁndings suggest that an augmentation in
ETA receptor-mediated ET-1 actions is a critical mechanism for the
enhancement of neointimal formation observed under ETB receptor-inhibited conditions inmale rats.We also demonstrated that the inhibi-
tion of ETB receptors in female rats abolished the sex differences associ-
ated with balloon injury-induced neointimal formation in rats (Kitada
et al., 2011). Moreover, we indicated that the augmentation of ETA
receptor-mediated actions rather than ETB receptor inhibition itself
contributed to the abolition of these sex differences in ETB receptor-
inhibited rats (Kitada et al., 2011). Thus, inhibiting the ETA receptor
system is one of the critical factors in the ERA-induced prevention of
neointimal formation in female as well as male rats. Although we did
not investigate the effects of a selective ETA or ETB receptor antagonist
on neointimal formation after the balloon injury in OVX rats in the
present study, we believed that inhibiting the ETA receptor system is a
critical factor for the prevention of neointimal formation, irrespective
of the presence or absence of ETB receptor inhibition.
Angiotensin II is one of the most important targets in the ﬁelds of
hypertension, and cardiovascular and renal diseases (Kobori et al.,
2007; von Lueder and Krum, 2013). The major actions of angiotensin
II are mediated by the angiotensin II type 1 (AT1) receptor, which
induces vasoconstriction, salt retention, aldosterone release, and cardio-
vascular and renal injuries (Kobori et al., 2007). Various basic and
384 K. Kitada et al. / Life Sciences 118 (2014) 379–385clinical studies demonstrated that ARB had vasoprotective effects as
well as antihypertensive actions (Hernandez Schulman et al., 2007,
Nakashima et al., 2006; von Lueder and Krum, 2013). Previous studies
reported that ARB and estrogen synergistically attenuated atherosclero-
sis and vascular remodeling following vascular injury in female mice by
inhibiting oxidative stress, and ERK and STAT activities (Liu et al., 2002;
Tsuda et al., 2005). We obtained similar results in the present study;
ARB signiﬁcantly inhibited neointimal formation following the balloon
injury in intact female rats, but not in OVX rats. Furthermore, neointimal
formation following the balloon injury in OVX rats was markedly less
with the combined treatment with ARB and 17β-estradiol than with
each monotherapy. On the other hand, one of the novel and important
ﬁndings in this study is that the combined treatment with the ERA
and ARB also markedly suppressed neointimal formation following
the balloon injury in OVX rats, although no combinational effects were
observed due to the ERA and 17β-estradiol. These results suggest that
ARB exerts a strong vasoprotective effect on the estrogen-existing con-
dition, but not on the estrogen-deﬁcient condition and also that the ERA
could replace estrogen to enhance the efﬁcacy of ARB. Taken together,
the ARB monotherapy only may not be sufﬁcient to reduce the risk of
vascular disease in women after menopause. The combined treatment
with the ERA and ARB could be a new useful target for reducing the
risk of vascular disease in postmenopausal women; however, further
understanding of the mechanisms responsible and clinical studies on
the present ﬁndings are required.
Oxidative stress plays an important role in the pathogenesis of vas-
cular disease via several mechanisms such as endothelial dysfunction,
inﬂammation, cell migration, growth, and apoptosis (Taniyama and
Griendling, 2003). An increase in NADPH oxidase and this enzyme-
derived reactive oxygen species were previously shown to be involved
in the development of neointimal formation after vascular injury
(Kurumazuka et al., 2006; Zalba et al., 2005). We previously demon-
strated that the inhibition of NADPH-dependent superoxide production
at an early phase after a balloon injury (2 days after the injury) was one
of the critical factors for preventing neointimal formation (Kurumazuka
et al., 2006). Furthermore, the attenuation of oxidative stress is known
to be involved in the vasoprotective effects of estrogen (Florian et al.,
2004). Thus, we hypothesize that differences in the vasoprotective ef-
fects of the ERA, ARB, 17β-estradiol, and combination therapy may be
due to differences in the ability to inhibit the initial rise in NADPH-
dependent superoxide production. As was observed with neointimal
formation, the ERA signiﬁcantly decreased NADPH-dependent superox-
ide production in OVX rats, but not in intact female rats, whereas ARB
exhibited opposite results. These results suggest that differences in the
vasoprotective effects of the ERA and ARBwere at least partly due to dif-
ferences in the attenuation of oxidative stress in the injured arteries of
intact female and OVX rats. In addition, the combined treatment with
the ERA or 17β-estradiol and ARB markedly decreased NADPH-
dependent superoxide production in the injured arteries of the OVX
groups. On the other hand, there were no combinational effects to de-
crease NADPH-dependent superoxide production observed due to the
combined treatment with 17β-estradiol and the ERA, which suggests
that the ERA or 17β-estradiol and ARB additively inhibit neointimal for-
mation, and this is at least partly due to the suppression of oxidative
stress. Further research to identify the detailed molecular mechanisms
of these ﬁndings is warranted.
Conclusions
Wedemonstrated that the ERA exhibited superior vasoprotective ef-
fects under the estrogen-deﬁcient condition than under the estrogen-
existing condition, and also that the ERA, similar to estrogen, induced
strong vasoprotective effects in combination with ARB. In addition, the
ERA and ARB additively attenuated neointimal formation following
the vascular injury, and this at least partly occurred due to the inhibition
of oxidative stress. Taken together, these results suggest that ERAs maybe an alternative therapy to prevent vascular disease in postmenopausal
women; however, further research regarding the detailed pharmaco-
logical mechanisms of ERAs and clinical studies are needed.
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